Status:
COMPLETED
Dose Finding Study Of CP-870,893, An Immune System Stimulating Antibody, In Combination With Paclitaxel And Carboplatin For Patients With Metastatic Solid Tumors
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Neoplasms
Eligibility:
All Genders
18-85 years
Phase:
PHASE1
Brief Summary
This is a dose-finding study; therefore, there is no hypothesis testing
Eligibility Criteria
Inclusion
- Patients with metastatic solid tumors, for whom carboplatin and paclitaxel are appropriate;
- Patients \>18 years of age;
- Good performance status;
- Adequate bone marrow and organ function
Exclusion
- Previous treatment with any other compound that targets CD40
- Current or planned concurrent treatment with any anticancer agent;
- Patients who have received bone marrow transplant;
- History of autoimmune disorder
- History (within the previous year) of heart failure or heart attack
- Cancer-associated coagulation disorders
Key Trial Info
Start Date :
November 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2009
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT00607048
Start Date
November 1 2007
End Date
July 1 2009
Last Update
March 27 2017
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Los Angeles, California, United States, 90025
2
Pfizer Investigational Site
Santa Monica, California, United States, 90404
3
Pfizer Investigational Site
Philadelphia, Pennsylvania, United States, 19104
4
Pfizer Investigational Site
San Antonio, Texas, United States, 78229